JCI - Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Go to JCI Insight

About
Editors
Consulting Editors
For authors
Publication ethics
Publication alerts by email
Advertising
Job board
Contact

100th anniversary
Current issue
Past issues
By specialty
Videos
- Conversations with Giants in Medicine
- Video Abstracts
Reviews
Viewpoint
Collections
Clinical Medicine

The Journal of Clinical Investigation
Current issue
Past issues
Specialties
Reviews
Review series
Videos
Conversations with Giants in Medicine
Video Abstracts
Collections
In-Press Preview
Clinical Medicine
Research Letters
Letters to the Editor
Editorials
Commentaries
Reviews
Viewpoints
Top read articles
Journal Details
About
Editors
Consulting Editors
For authors
Publication ethics
Publication alerts by email
Advertising
Job board
Contact

Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Brian J. Druker, Nicholas B. Lydon

Brian J. Druker, Nicholas B. Lydon

Published January 1, 2000
Citation Information: J Clin Invest. 2000;105(1):3-7. https://doi.org/10.1172/JCI9083.

View: Text | PDF

Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Text
PDF

Abstract

Authors

Brian J. Druker, Nicholas B. Lydon

×

Options: View larger image (or click on image) Download as PowerPoint

Selected small-molecule ATP-competitive protein kinase inhibitors in dev...

Selected small-molecule ATP-competitive protein kinase inhibitors in development

Copyright © 2024 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts